| Japanese |
|---|
| Title | 心筋脂肪酸代謝イメージング剤β-メチル-p-(123I)-ヨードフェニルペンタデカン酸の第1相臨床試験 |
|---|
| Subtitle | 原著 |
|---|
| Authors | 鳥塚莞爾*, 米倉義晴**, 西村恒彦***, 玉木長良**, 植原敏勇***, 池窪勝治****, 日野恵**** |
|---|
| Authors(kana) | |
|---|
| Organization | *福井医科大学, **京都大学医学部放射線核医学, ***国立循環器病センター放射線診療部, ****神戸市立中央市民病院核医学科 |
|---|
| Journal | 核医学 |
|---|
| Volume | 28 |
|---|
| Number | 7 |
|---|
| Page | 681-690 |
|---|
| Year/Month | 1991/7 |
|---|
| Article | 原著 |
|---|
| Publisher | 日本核医学会 |
|---|
| Abstract | 「要旨」心筋脂肪酸代謝を評価するために開発されたβ-メチル-p-(123I)-ヨードフェニルペンタデカン酸 (123I-BMIPP) の安全性および体内薬物動態を検討するために, 健常男子6例を対象に第1相臨床試験を実施した. 本剤は投与後速やかに心筋へ集積し, 1.5時間後に5.4±0.6%の集積率を示した. 投与3時間後の集積率は5.1±0.4%と心筋からの洗い出しは緩徐であった. 心筋以外では肝臓に集積したほか, 筋肉にも淡く集積したが, 他の臓器への著明な集積はみられなかった. 本剤投与後早期, および3時間において鮮明な心筋プラナー像およびSPECT像が得られた. MIRD法により算出された本剤による吸収線量は, いずれの臓器においても201Tlに比し低値であった. また, 本剤に起因すると考えられる副作用や臨床検査値の異常変動はみられなかった. 本剤は安全性に問題なく, 明瞭な心筋像が得られ, 心筋脂肪酸代謝の評価に有用な放射性医薬品であると考えられた. |
|---|
| Practice | 臨床医学：一般 |
|---|
| Keywords | β-methyl-p-(123I)-iodophenyl-pentadecanoic acid (123I-BMIPP), myocardial fatty acid metabolism, Phase I study, Biodistribution, Safety evaluation. |
|---|
| English |
|---|
| Title | The Phase 1 Study of β-methyl-p-(123I)-iodophenyl-pentadecanoic Acid (123I-BMIPP) |
|---|
| Subtitle | Original Articles |
|---|
| Authors | Kanji TORIZUKA*, Yoshiharu YONEKURA**, Tsunehiko NISHIMURA***, Nagara TAMAKI**, Toshiisa UEHARA***, Katsuji IKEKUBO***, Megumu HINO**** |
|---|
| Authors(kana) | |
|---|
| Organization | *Fukui Medical School, **Department of Nuclear Medicine, School of Medicine, Kyoto University, ***Department of Radiology, National Cardiovascular Center, ****Department of Nuclear Medicine, Kobe City General Hospital |
|---|
| Journal | The Japanese Journal of nuclear medicine |
|---|
| Volume | 28 |
|---|
| Number | 7 |
|---|
| Page | 681-690 |
|---|
| Year/Month | 1991/7 |
|---|
| Article | Original article |
|---|
| Publisher | THE JAPANESE SOCIETY OF NUCLEAR MEDICINE |
|---|
| Abstract | [Summary] Phase 1 study of β-methyl-p-(123I)-iodophenyl-pentadecanoic acid (123I-BMIPP), a new radio-pharmaceutical developed for the evaluation of myocardial fatty acid metabolism, was performed in six normal volunteers to evaluate its biodistribution and safety. After intraveneous injection of 111MBq of 123I-BMIPP, the agent accumulated to the myocardium rapidly (5.4 +- 0.6% at 1.5 hr after injection) and was washed-out slowly (5.1 +- 0.4% at 3.0 hr). 123I-BMIPP demonstrated no significant accumulation to any specific organs other than myocardium, liver and muscle. Myocardium was clearly visualized in the planar and SPECT images obtained 30 min and 3 hrs after injection. The absorption doses from 123I-BMIPP estimated by MIRD method were lower than those from 201Tl in all organs. Neither adverse reactions nor abnormal clinical laboratory findings were found in the safety evaluation. These results suggest 123I-BMIPP is a promising agent for evaluating myocardial fatty acid metabolism. |
|---|
| Practice | Clinical medicine |
|---|
| Keywords | β-methyl-p-(123I)-iodophenyl-pentadecanoic acid (123I-BMIPP), myocardial fatty acid metabolism, Phase I study, Biodistribution, Safety evaluation. |
|---|